163 related articles for article (PubMed ID: 16864057)
1. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Ueno NT; Hosing C; Khouri IF; Couriel D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE
Haematologica; 2008 Feb; 93(2):257-64. PubMed ID: 18223284
[TBL] [Abstract][Full Text] [Related]
2. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
Cutler C; Li S; Ho VT; Koreth J; Alyea E; Soiffer RJ; Antin JH
Blood; 2007 Apr; 109(7):3108-14. PubMed ID: 17138818
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.
Storb R; Gyurkocza B; Storer BE; Maloney DG; Sorror ML; Mielcarek M; Martin PJ; Sandmaier BM
Biol Blood Marrow Transplant; 2013 May; 19(5):792-8. PubMed ID: 23416851
[TBL] [Abstract][Full Text] [Related]
4. T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies.
Katsanis E; Sapp LN; Reid SC; Reddivalla N; Stea B
Front Pediatr; 2020; 8():282. PubMed ID: 32582591
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation in follicular lymphoma.
Khouri IF
Best Pract Res Clin Haematol; 2011 Jun; 24(2):271-7. PubMed ID: 21658623
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.
Toor AA; Sabo RT; Chung HM; Roberts C; Manjili RH; Song S; Williams DC; Edmiston W; Gatesman ML; Edwards RW; Ferreira-Gonzalez A; Clark WB; Neale MC; McCarty JM; Manjili MH
Biol Blood Marrow Transplant; 2012 May; 18(5):794-804. PubMed ID: 22005648
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease.
Magenau J; Jaglowski S; Uberti J; Farag SS; Riwes MM; Pawarode A; Anand S; Ghosh M; Maciejewski J; Braun T; Devenport M; Lu S; Banerjee B; DaSilva C; Devine S; Zhang MJ; Burns LJ; Liu Y; Zheng P; Reddy P
Blood; 2024 Jan; 143(1):21-31. PubMed ID: 37647633
[TBL] [Abstract][Full Text] [Related]
8. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
Alyea EP; DeAngelo DJ; Moldrem J; Pagel JM; Przepiorka D; Sadelin M; Young JW; Giralt S; Bishop M; Riddell S
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1037-69. PubMed ID: 20580849
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.
Ballen K; Mendizabal AM; Cutler C; Politikos I; Jamieson K; Shpall EJ; Dey BR; Attar E; McAfee S; Delaney C; McCarthy P; Ball ED; Kamble R; Avigan D; Maziarz RT; Ho VT; Koreth J; Alyea E; Soiffer R; Wingard JR; Boussiotis V; Spitzer TR; Antin JH
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1851-8. PubMed ID: 22766223
[TBL] [Abstract][Full Text] [Related]
10. Effects of spleen status on early outcomes after hematopoietic cell transplantation.
Akpek G; Pasquini MC; Logan B; Agovi MA; Lazarus HM; Marks DI; Bornhaeüser M; Ringdén O; Maziarz RT; Gupta V; Popat U; Maharaj D; Bolwell BJ; Rizzo JD; Ballen KK; Cooke KR; McCarthy PL; Ho VT
Bone Marrow Transplant; 2013 Jun; 48(6):825-31. PubMed ID: 23222382
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.
Slavin S; Ackerstein A; Or R; Shapira MY; Gesundheit B; Askenasy N; Morecki S
Cancer Immunol Immunother; 2010 Oct; 59(10):1511-9. PubMed ID: 20563804
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host disease following liver transplantation: A systematic review of literature.
Kneifel F; Vogel T; Bormann E; Becker F; Houben P; Flammang I; Slepecka P; Eichelmann AK; Brockmann JG; Pascher A
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37755878
[TBL] [Abstract][Full Text] [Related]
13. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
14. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
[TBL] [Abstract][Full Text] [Related]
15. Acute graft-versus-host disease: new treatment strategies.
Paczesny S; Choi SW; Ferrara JL
Curr Opin Hematol; 2009 Nov; 16(6):427-36. PubMed ID: 19812490
[TBL] [Abstract][Full Text] [Related]
16. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
